Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Basic & Translational

Do we still need to assess for lung shunt in all Y90 Liver treatment’s ?

Mark Tann, Paul Haste and mitchell rice
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 1315;
Mark Tann
1Radiology Indiana Univ Indianapolis IN United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Haste
1Radiology Indiana Univ Indianapolis IN United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
mitchell rice
1Radiology Indiana Univ Indianapolis IN United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1315

Introduction: Since the introduction of transarterial radioembolization (TARE) for the treatment of liver malignancies a key pre therapy step has been to assess for potential lung shunting with a hepatic arterial injection of Tc-MAA and a quantitative image assessment of the radiopharmaceutical distribution. However this causes the need for additional costs and morbidity as well as a treatment delay. Literature and our experience has suggested that a critical evaluation of the cross sectional imaging prior to therapy may help predict when significant shunting to the lungs may be present. We wanted to evaluate which imaging findings were key for prediction of significant lung shunting.

Methods: We retrospectively evaluated 823 lung shunt studies performed at our institution over a 7 year period and identified those with a substantial lung shunt (>/= 15%). We then evaluated the pre-treatment cross sectional imaging for the type, size, number and location of liver tumors, as well as for the presence of vascular tumor involvement.

Results: Of the 823 studies only 58 (7%) had significant (>15%) lung shunting. Of these, 45 (76%) were primary liver tumors, most were hepatocellular carcinoma with only one cholangiocarcinoma. The rest 13 (24%) were metastatic disease with neuroendocrine the dominant type (46%). Tumor size larger than 10 cm was seen in 24 (41%) and greater than 7cm seen in 30 (52%). In the smaller tumor group 38 ( <7cm), multiple lesions/diffuse disease was seen in 11 (29%), vascular pathology in 6 (16%) and poor location , such as segment one, was noted in 6 (16%). In the majority of cases of significant shunting, abnormal vascular shunting was also noted on the angiography images.Discussion:As we have seen the presence of significance of lung shunting is overall very low. Additionally, there are key predictive factors on the cross sectional imaging, such as tumor size and vascular pathology which can predict its likelihood. There are also predictive findings for significant shunting noted on the angiographic images. Therefore it is not clear if lung shunting evaluation is therefore warranted in every case of TARE, especially if there is an increased awareness of these predictive factors.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 60, Issue supplement 1
May 1, 2019
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Do we still need to assess for lung shunt in all Y90 Liver treatment’s ?
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Do we still need to assess for lung shunt in all Y90 Liver treatment’s ?
Mark Tann, Paul Haste, mitchell rice
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 1315;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Do we still need to assess for lung shunt in all Y90 Liver treatment’s ?
Mark Tann, Paul Haste, mitchell rice
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 1315;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Basic & Translational

  • TIM3-targeted combined-modality radioimmunotherapy in hepatocellular carcinoma
  • Al18F-labeled á-MSH peptide derivative for early detection of melanoma
  • Combination of 177Lu-lilotomab satetraxetan with rituximab synergistically improves in-vivo therapeutic efficacy in a rituximab-resistant non-Hodgkin lymphoma (NHL) model
Show more Oncology: Basic & Translational

Image-Guided Therapy Posters

  • Randomized Phase 3 Trial of 68Ga-PSMA-11 PET/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning [PSMA-SRT]: Study Protocol
  • Imaging and therapeutic efficacy of 64Cu-labeled melanin nanoparticles in A431 tumor-bearing nude mouse models
Show more Image-Guided Therapy Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire